HH Biotechnology Holdings Company
HH Biotechnology Holdings Company
Your view on HHBT
Overview
What the company does, where it operates, and who runs it.
About HH Biotechnology Holdings Company
- Industry
- Real Estate - Services
- Sector
- Real Estate
- CEO
- Sheng Jiang
- Headquarters
- President Building, Shenyang, CN
- Industry
- Real Estate - Services
- Sector
- Real Estate
- CEO
- Sheng Jiang
- Headquarters
- President Building, Shenyang, CN
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics.
The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the People's Republic of China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for HH Biotechnology Holdings Company, and the rating behind it. HHBT last traded at $0.0001, 0.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for HH Biotechnology Holdings Company. Starting points for HH Biotechnology Holdings Company: P/E 0.0, EPS $0.18, beta 4.30 — an Real Estate - Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for HH Biotechnology Holdings Company. HH Biotechnology Holdings Company does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for HH Biotechnology Holdings Company. Trailing twelve-month EPS for HH Biotechnology Holdings Company stands at $0.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for HH Biotechnology Holdings Company. HH Biotechnology Holdings Company has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
HH Biotechnology Holdings Company valued side by side against its closest peers. HH Biotechnology Holdings Company is measured against Real Estate - Services peers within the Real Estate sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold HH Biotechnology Holdings Company, and how their positions are changing. At a $1,406 market value, institutional positions materially move HH Biotechnology Holdings Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by HH Biotechnology Holdings Company executives and directors. Shares of HH Biotechnology Holdings Company have traded between $0.0001 and $0.0002 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming HH Biotechnology Holdings Company. HH Biotechnology Holdings Company is a $1,406 Real Estate company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming HH Biotechnology Holdings Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for HH Biotechnology Holdings Company. Coverage tracks HH Biotechnology Holdings Company within Real Estate - Services (Real Estate). Press releases and market coverage, newest first.